[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565941":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":24,"locations":30,"responsibleParty":46,"collaborators":51,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":18,"enrollmentInfo":63,"targetDuration":18,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":75,"overallStatus":79,"whyStopped":18,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"University Medical Center Ho Chi Minh City (UMC)","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1 (1-Month DAPT): DAPT De-escalation (Intervention Group)","EXPERIMENTAL","Patients in this group will receive DAPT (aspirin and a P2Y12 inhibitor) for 1 month, followed by monotherapy with a P2Y12 inhibitor for the remaining 11 months.",[13],"Drug: DAPT de-escalation",{"label":15,"type":16,"description":17,"interventionNames":18},"Group 2 (12-Month DAPT): Standard DAPT (Control Group)","NO_INTERVENTION","Patients in this group will continue with DAPT (aspirin and a P2Y12 inhibitor) for the full 12 months.",null,[20],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":18},"DRUG","DAPT de-escalation",[9],[25],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},"Vu H Vu, MD, PhD","CONTACT","+84908431304","vu.vh@umc.edu.vn",[31],{"facility":32,"status":18,"city":33,"state":18,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"University Medical Center of Ho Chi Minh City","Ho Chi Minh City","70000","Vietnam","VN",{"type":38,"coordinates":39},"Point",[40,41],106.62965,10.82302,{"lat":41,"lon":40},[44],{"name":26,"role":27,"phone":45,"phoneExt":18,"email":29},"+84‭908431304‬",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":50,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Vu Hoang Vu","Head of Interventional Cardiology Department, PhD MD","University of Medicine and Pharmacy at Ho Chi Minh City",[52],{"name":50,"class":6},"100565941","efficacy-and-safety-of-shortening-dual-antiplatelet-therapy-duration-with-ivus-guidance-in-pci-patients-100565941",false,"NCT06648720","Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients","Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients: a Multicenter, Randomized Controlled Trial","SHORTDAPT","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).\n* Patients with the following clinical indications for PCI:\n\n  * Unstable Angina: Prolonged chest pain at rest, new-onset angina within the past 2 months, or increasing frequency\u002Fseverity of angina attacks.\n  * Acute Myocardial Infarction (MI): With or without ST-elevation.\n  * Chronic Coronary Syndrome: Requiring coronary revascularization.\n* Patients who agree to participate and provide informed consent.\n\nExclusion Criteria:\n\n* Inability to Provide Informed Consent: Patients who are unable or unwilling to provide consent.\n* Neurological Complications: Stroke or any permanent neurological deficits within the last 3 months.\n* Coronary Artery Bypass Graft Surgery: History of CABG surgery.\n* Planned Surgery: Patients who have surgeries planned within the next 12 months.\n* Severe Chronic Kidney Disease: Patients with an estimated glomerular filtration rate (eGFR) of less than 20 ml\u002Fmin\u002F1.73 m² or patients on dialysis.\n* Chronic Anticoagulation Therapy: Patients requiring chronic oral anticoagulation (e.g., warfarin, DOACs) beyond DAPT.\n* Thrombocytopenia: Platelet count less than 100,000\u002Fmm³.\n* Contraindications to Antiplatelet Therapy: Allergy or intolerance to aspirin or P2Y12 inhibitors.\n* Liver Disease: Patients with cirrhosis or significant liver dysfunction.\n* Limited Life Expectancy: Patients with a life expectancy of less than 12 months due to other non-cardiac conditions.\n* Other Medical Conditions: Any condition that might interfere with adherence to the study protocol or follow-up schedule.","ALL","18 Years",{"count":64,"type":65},3566,"ESTIMATED","INTERVENTIONAL",[68],"NA","This study is designed to assess the efficacy and safety of de-escalating dual antiplatelet therapy (DAPT) at 1 month compared to the standard 12 months of therapy in patients undergoing percutaneous coronary intervention (PCI) guided by intravascular ultrasound (IVUS). The main outcomes measured will include major adverse cardiovascular and cerebrovascular events (NACCE), bleeding events, and target vessel failure (TVF). The goal is to evaluate whether a shorter duration of DAPT is non-inferior to the standard 12-month regimen in preventing ischemic events while reducing the incidence of bleeding.",[71,72,73,74],"Coronary Arterial Disease (CAD)","Percutaneous Coronary Intervention (PCI)","Intravascular Ultrasound","Dual Antiplatelet Therapy",[76,77,78,71],"Shortening DAPT duration","Intravascular Ultrasound (IVUS)","Percutaenous Coronary Intervention (PCI)","NOT_YET_RECRUITING","2024-10-16",{"date":82,"type":83},"2024-10-18","ACTUAL",{"date":85,"type":65},"2025-03-01",{"date":87,"type":65},"2029-03-01",{"name":5,"class":6},1]